Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Independent Analysis of Permian Well results

17 Feb 2010 07:41

RNS Number : 2644H
ViaLogy PLC
17 February 2010
 



VIALOGY PLC

 

INDEPENDENT ANALYSIS VERIFIES VIALOGY

PERMIAN WELL PREDICTIONS

 

London, February 17. ViaLogy (LSE:VIY) announces the start of oil production from a recently completed successful well in the Strawn formation in Texas, and independent confirmation of ViaLogy's reservoir attribute predictions. The client specified that ViaLogy find Strawn with significant thickness to make a commercially successful well; that major zones of porosity over 4% be identified; and that the selected Strawn section exhibit natural fracturing to enable optimal production.

Final well and formation micro-imaging (FMI) logs, done by Halliburton, show that QuantumRD directly detected and predicted a 220 foot continuous Strawn section. Within this section, ViaLogy's pre-drilling analysis located high porosity limestone zones - totaling over 80 feet with more than 4% porosity. Logging showed a continuous zone of 50 feet with greater than 6% porosity, and reaching 10 to 12%. The ability of the technology to find and distinguish between such small variations in limestone porosity demonstrates QuantumRD's sensitivity, and its utility in mapping the Strawn and other formations where porosity is a critical factor in determining a well's economic viability. In addition, the analysis also verified that QuantumRD located natural fractures enhancing the reservoir's permeability and enabling extraction to be optimized. ViaLogy's contract prohibits identifying the client.

This ViaLogy-positioned well is in the Permian Basin, one of the largest structural basins and most prolific petroleum provinces in North America, extending approximately 86,000 sq miles over Texas and New Mexico. It sits in the naturally fractured Spraberry Trend Area in west Texas covering approximately 2,500 square miles over a six county area. Estimated to hold 6-10 billion bbls of oil, this trend area has huge potential for future recovery as only about 700 million bbls have been produced over the past 50 years. This is due in part to the analytical challenges of finding high porosities and developing economically viable wells in the carbonate, limestone and/or dolomite platform, and to natural fractures in a rock matrix with inherently low permeability. Also, unlike conventional faulted sandstone reservoirs, the Permian platform is a stratigraphic formation with discontinuities over small areas. Current exploration technologies and basin geology models provide limited insight for positioning individual wells and offsets, as the formation properties change unpredictably due to complex cementation and matrix dissolution processes. QuantumRD's more innovative computational approach to characterize the subsurface and locate drilling targets should assist in the Permian Basin's exploitation.

Robert Dean, ViaLogy CEO, said, "Independent confirmation of QuantumRD's Strawn success further validates the technology's power. ViaLogy's work is done on the basis of specific client drilling requirements - they tell us what quantifiable characteristics to find, such as porosity, and this can vary depending upon the location, formation characteristics and land area where a client wants to drill. We offer an 'energy solution' - the ability to identify drilling sites, depths, porosities and trends based on a synergistic integration of rock physics, 3-D and multi-component seismic data, and depositional geology. In this well we used QuantumRD, our proprietary weak signal detection technology, to locate regions of high porosity within a range of carbonate sizes that are key for positioning successful Permian wells."

He added, "Our technology can be applied to virtually any hydrocarbon formation, and we have a growing customer list and backlog that will take us into other areas of the Permian and other completely different areas. We are now finalizing our next drilling recommendation location on this particular Strawn prospect, and we intend to deliver another success to our client. We are also in discussions with several exploration & production firms to deliver QuantumRD analysis on the Permian."

 

ViaLogy PLC

 

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

 

 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

 

 

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com.

 

 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results,

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLDDLBFBLFXBBK
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.